<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01543126</url>
  </required_header>
  <id_info>
    <org_study_id>Fudan BR2011-06</org_study_id>
    <nct_id>NCT01543126</nct_id>
  </id_info>
  <brief_title>IL-6 and IL-8 Level of Blood and Pleural Effusion During Chemotherapy in Metastatic Breast Cancer</brief_title>
  <official_title>A Prospective Study Assessing the Correlation Between Disease Prognosis and the Level of IL-6 and IL-8 Level in Blood and Pleural Effusion Before and After Chemotherapy in Patients With Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Change of IL-6 and IL-8 level in blood and pleural effusion before and after chemotherapy
      correlate with the prognosis of the disease
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the correlation between the disease prognosis and the level of IL-6 and IL-8 in
      blood and pleural effusion before and after chemotherapy in patients with metastatic breast
      cancer
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    it's too slow to enroll suitable patients into this study
  </why_stopped>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>level of IL-6 and IL-8</measure>
    <time_frame>2 days</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">9</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>pleural effusion</arm_group_label>
    <description>patients with pleural effusion</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      pleural effusion
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        metastatic breast cancer patients with pleural effusion
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female between 18 and 70 years old;

          -  Patients with histologic proved metastatic breast cancer;

          -  Pleural effusion with the volume of more than 1000ml, as documented by CT, X ray or
             ultrasound;

          -  There are no other diseases which cause the elevation of IL-6 or IL-8, such as
             cirrhosis of liver, anaphylactoid purpura, acute pancreatitis;

          -  With at least one measurable disease according to RECIST criteria,

          -  Normal laboratory results:ANC≥2.0×109/L,Hb≥80g/L,plt≥100×109/L,TB&lt;UNL (&lt;1.5 x UNL in
             patients with liver mets),ALT/AST&lt; 1.5 x UNL (&lt;2.5x UNL in patients with liver
             mets),AKP&lt;5 x UNL(except bone mets),Cr&lt;UNL;

          -  Normal functions with heart, liver,renal and bone marrow;

          -  Got ICF before enrollment;

          -  Life expectancy more than 12 weeks.

        Exclusion Criteria:

          -  Pregnant or breast-feeding women or positive serum pregnancy test;

          -  Uncontrolled brain metastases;

          -  No recovery from previous radiation or accepted radiation within 4 weeks before
             enrollment;

          -  Participation in any investigational drug study within 4 weeks preceding treatment
             start;

          -  Concurrent other malignancy at other sites or previous other cancer within the last 5
             years, with the exception of adequately treated in situ carcinoma of cervix uteri or
             basal or squamous cell carcinoma of the skin;

          -  Serious uncontrolled intercurrent infections;

          -  Poor compliance.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xichun Hu, MD.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2012</study_first_submitted>
  <study_first_submitted_qc>February 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2012</study_first_posted>
  <last_update_submitted>July 24, 2013</last_update_submitted>
  <last_update_submitted_qc>July 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xichun Hu</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Pleural Effusion</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

